Urothelial
Forager-2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration (JZVD)
Trial overview
Clinical Area
Medical Oncology
Disease
Genitourinary (GU)
Disease site
Urothelial
Study Phase
III
Trial Identifiers
Registration number: NCT07218380
Principal Investigator(s)
··
··